DigiLum is Lumeda's photodynamic therapy system for non-small cell lung cancer with pleural disease.
Competing Products
Lumeda
Lumeda Inc.: Advancing photodynamic therapy for thoracic malignancies with our breakthrough product, DigiLum.
Founded
2020Lumeda Inc.: Advancing photodynamic therapy for thoracic malignancies with our breakthrough product, DigiLum.
Founded to commercialize novel medical device technology, Lumeda Inc. focuses on advancing photodynamic therapy (PDT) for treating non-small cell lung cancer (NSCLC) and other thoracic malignancies. The company's core mission is to expand the use of PDT, a proven and safe therapy free of systemic toxicities, into new sites and indications. Lumeda's flagship product, DigiLum, is a breakthrough light dosimetry device designed to activate photosensitizer drugs, enhancing the efficacy of PDT and improving patient outcomes.
Lumeda has attracted notable investors and industry experts who support its innovative approach to cancer treatment. The company has achieved significant milestones, including the development and initial commercialization of DigiLum. Lumeda's impact lies in its potential to offer a safer, more effective therapeutic option for patients with thoracic malignancies, addressing a critical need in the oncology market and potentially improving survival rates and quality of life for many patients globally.
Companies similar to Lumeda include Theralase, SpectraCure, Modulight and LumiThera.
Lumeda was founded in 2020.
Lumeda's headquarters is located in Rocky Hill, CT, US.
Lumeda's most recent funding round was for $4.3M (USD) in April 2021.
As of Apr 8, 2021, Lumeda has disclosed funding of $7.4M (USD). Undisclosed round amounts are excluded.
Lumeda has 11 employees as of Feb 5, 2024.
LumiThera
lumithera.com